Editorial
Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics
Table 1
Types of hematological malignancies and rate of diagnosis for all newly diagnosed neoplasms within the United States.
| | Hematological malignancy | Percent of hematological malignancies | Percent of malignancy |
| | Lymphomas | 51% | | | Hodgkin’s Lymphoma | | 14% | | Non-Hodgkin’s Lymphoma | | 86% | | Leukemias | 33% | | | Acute lymphoblastic leukemia (ALL) | | 11% | | Acute myelogenous leukemia (AML) | | 36% | | Chronic lymphoblastic leukemia (CLL) | | 30% | | Chronic myelogenous leukemia (CML) | | 11% | | Other | | 11% | | Myelomas | 15% | | | Total | | 100% |
|
|
(National Cancer Institute 2007–2011 rates http://seer.cancer.gov/ and The Leukemia and Lymphoma Society 2014 rates http://www.lls.org/).
|
